Guideline Based Hereditary Cancer Panel
Also known as: Inherited Cancer, Multi-Gene Cancer, BRCA, HBOC, BRACA
Use
This multigene panel is used to identify individuals with a hereditary predisposition to cancer when personal or family history suggests inherited susceptibility but does not indicate a specific syndrome. It is particularly valuable when prior single-gene testing was negative despite high clinical suspicion. It aids in risk assessment in individuals with personal or familial cancer histories that are inconclusive for a specific hereditary cancer syndrome.
Special Instructions
Informed consent is required and genetic counseling is recommended prior to testing. Consultation with a Quest genomic science specialist is available via Quest Genomics Client Services at 1.866.GENE.INFO. If a familial mutation is known, consider the Hereditary Cancer Single Site(s) test (test code 93945).
Limitations
This test is limited to analysis of the 32 genes on the panel and does not assess other genes associated with hereditary cancer. Not all gene regions may be examined, so variants in unexamined regions may be missed. Rare or novel variants may have uncertain clinical significance. False-positive or false-negative results are possible. Results must be interpreted in context of clinical and family history, and additional genetic testing may be appropriate.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided